GGrantIndex
Sort

64,565 grants matching drug discovery

Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment

$1,516,817
D. Martin Watterson · Northwestern University At Chicago · U01 · FY2022 · AG

Organic Pseudometals to Sustain and Transform Small-Molecule Drug Synthesis

$1,516,500
Richard Liu · Harvard University · DP2 · FY2025 · GM

Molecular and Cellular Mechanisms of Osteoporosis

$1,516,128
Stavros C. Manolagas · Univ Of Arkansas For Med Scis · P01 · FY2015 · AG

Defining pediatric intestinal failure natural history

$1,515,663
Simon Horslen · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · FD

Modeling diabetes using an integrated plate system

$1,515,000
James M Wells · Cincinnati Childrens Hosp Med Ctr · UH3 · FY2022 · DK

Genetic Modifiers of Initiation and Progression of Mammary Cancer

$1,513,839
Kent W Hunter · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Defining and Manipulating Epigenomic Regulators in Endogenous Systems

$1,513,786
Jordan Leslie Meier · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Clark Atlanta University Biomedical Science Development

$1,513,670
Carlton E. Brown · Clark Atlanta University · G12 · FY2009 · RR

FAMILIAL PARKINSON'S DISEASE: CLUES TO PATHOGENESIS

$1,513,192
Brigham And Women'S Hospital · P50 · FY2003 · NS

Contraception by Blockade of Periovulatory Events in Primates

$1,512,284
Richard L Stouffer · Oregon Health & Science University · U54 · FY2012 · HD

Contraception by Blockade of Periovulatory Events in Primates

$1,512,284
Richard L Stouffer · Oregon Health & Science University · U54 · FY2016 · HD

Contraception by Blockade of Periovulatory Events in Primates

$1,512,284
Richard L Stouffer · Oregon Health & Science University · U54 · FY2015 · HD

Vascular Biology in Cancer

$1,512,233
Pengnian Lin · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis

$1,512,192
William E. Carson · Ohio State University · UM1 · FY2018 · CA

CDI Type II: Cyber-Engineering Functional Nanoparticles for Targeted Drug Delivery

$1,512,150
Roland Faller · University Of California-Davis · · FY2009 · ENG

Dietary Biomarkers Development Center at Harvard University

$1,512,125
Frank B Hu · Harvard School Of Public Health · U2C · FY2021 · DK

Technolgy Implementation

$1,512,032
Hanlee Ji · Stanford University · P01 · FY2015 · HG

Development of Innovative Resources to Advance MDS Research

$1,511,993
Marie Bleakley · Fred Hutchinson Cancer Center · RC2 · FY2024 · DK

Molecular Pathogenesis

$1,511,881
Edward H Oldfield · Neurological Disorders And Stroke · Z01 · FY2007 · NS

Target Identification via Haplo Insufficiency Profiling

$1,511,752
Stanford University · R33 · FY2002 · CA

Center for Testing Potential Anti-Aging Interventions

$1,511,552
Randy Strong · University Of Texas Hlth Science Center · U01 · FY2020 · AG

Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis

$1,511,058
Gregory Paul Downey · National Jewish Health · UH3 · FY2021 · TR

Novel Protease Inhibitors as SARS Therapeutics

$1,510,698
Michael E. Johnson · University Of Illinois At Chicago · P01 · FY2008 · AI

Molecular and Cellular Mechanisms of Vascular Anomalies

$1,510,559
Bjorn R Olsen · Harvard Medical School · P01 · FY2010 · AR

Planning Study for the Development of Sigma 2 ligands as Analgesics

$1,510,066
Kevin Joseph Tidgewell · University Of Kentucky · R61 · FY2023 · NS